Skip to main content
. 2023 Jun 9;14:1194123. doi: 10.3389/fimmu.2023.1194123

Figure 4.

Figure 4

Combination of pretreatment PD-L1 expression and circulating chemokine CXCL12 levels improved the prediction capability of immunotherapy outcomes. (A) Response or nonresponse and (B) DCB or NDB of the patient proportions in different groups stratified by the PD-L1 TPS plus CXCL12 level at baseline. The patients were divided into four groups: group 1 (TPS≥1% and CXCL12 bottom 67%); group 2 (TPS<1% and CXCL12 bottom 67%); group 3 (PD-L1≥1% and CXCL12 top 33%); and group 4 (PD-L1<1% and CXCL12 top 33%). Groups 2 and 3 were pooled together. AUC analyses of PD-L1 expression, CXCL12 level and PD-L1 expression plus CXCL12 level to predict (C) response/nonresponse or (D) DCB/NDB. TPS, tumor proportion score; AUC, area under the curve; DCB, durable clinical benefit. NDB, no durable benefit.